Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Launches Menopause Tablet Julina in Japan; First Market To Launch In World

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Bayer HealthCare of Osaka launched its menopause and postmenopausal treatment Julina (estradiol E2) in Japan Sept. 16, making Japan the first market to launch the drug in the world, the company announced

You may also be interested in...



Japan To List Nine Composites For National Health Insurance Coverage

TOKYO - At its Dec. 3 plenary meeting, Chuikyo (the Central Social Insurance and Medical Council), the government-private body that sets Japan's medical and pharmaceutical policies, approved the listing of nine composites for 13 pharmaceutical products, including the relisting of Fujimoto's Thaled (thalidomide) for multiple myeloma

Japan To List Nine Composites For National Health Insurance Coverage

TOKYO - At its Dec. 3 plenary meeting, Chuikyo (the Central Social Insurance and Medical Council), the government-private body that sets Japan's medical and pharmaceutical policies, approved the listing of nine composites for 13 pharmaceutical products, including the relisting of Fujimoto's Thaled (thalidomide) for multiple myeloma

Pfizer And Astellas Drugs Added To Japan MHLW's NHI Coverage List

TOKYO - Japan's Ministry of Health, Labor and Welfare released details of 11 new drugs approved at the Aug. 27 Central Social Insurance Medical Council (Chuikyo) general meeting for National Health Insurance coverage listing

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel